EGFR -mutated lung cancers resistant to osimertinib through EGFR -C797S respond to 1 st generation reversible EGFR inhibitors but eventually acquire EGFR -T790M/C797S in preclinical models and clinical samples
暂无分享,去创建一个
C. Paweletz | P. Jänne | S. Kobayashi | G. Oxnard | Susumu S. Kobayashi | Ciric To | Mierzhati Mushajiang | P. VanderLaan | Costa | B. Daniel | C. Lau | Jason Shpilsky | Deepa Rangachari